Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aceclofenac. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 5/20 | 0.72 |
| ▸ | TTR | P02766 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | CXCL8 | P10145 | 3/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.72 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.72 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.72 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.72 |
| ▸ | ALB | P02768 | 1/20 | 0.72 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.72 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.72 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.72 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aceclofenac SCHEMBL29364020 | 1.00 | TTR (1.00) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL27918955 | 0.99 | TTR (0.97) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL16697727 | 0.99 | TTR (0.97) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL2905138 | 0.99 | TTR (0.97) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL28443210 | 0.99 | TTR (0.97) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL5081852 | 0.97 | TTR (0.95) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL15268397 | 0.97 | TTR (0.95) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL28873275 | 0.97 | TTR (0.95) | TTRCYP2C9USP2LMNATBXA2R | |
| Aceclofenac SCHEMBL29775490 | 0.93 | TTR (0.86) | TTRCYP2C9USP2LMNATBXA2R | |
| SCHEMBL26655544 | 0.89 | TTR (0.80) | TTRCYP2C9USP2LMNATBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 13536 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130928-A1 | COMBINATION OF AKR1C3 ACTIVATED ANTICANCER PRODRUG COMPOUND AND ANALGESIC DRUG FOR TREATING CANCER PATIENTS ACCOMPANIED BY PAIN | ASCENTAWITS PHARMACEUTICALS LTD (CN) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-20260108504-A1 | ENTERIC COATED TABLET WITH ACECLOFENAC AND PARACETAMOL TABLET AND PROCESS OF PREPARATION THEREOF | ATOZ PHARMACEUTICALS PVT LTD (IN) | 2026-04-23 | — | — | US | claimed |
| US-12605432-B2 | Combinations for antigen based therapy | DIAMYD MEDICAL AB (SE) | 2026-04-21 | — | — | US | claimed |
| US-12600696-B2 | Aromatic compounds | Xeniopro GmbH (DE) | 2026-04-14 | — | — | US | claimed |
| US-12582717-B2 | Protein based excipient for active pharmaceutical ingredients | DISPERSOME IP APS (NL) | 2026-03-24 | — | — | US | claimed |
| US-20260048013-A1 | PHARMACEUTICAL FORMULATION WITH IMPROVED SOLUBILITY AND BIOAVAILABILITY | CONSEJO SUPERIOR INVESTIGACION (ES) | 2026-02-19 | — | — | US | claimed |
| EP-4691462-A1 | SILYBIN-CONTAINING COMPOSITION | Tianjin Tasly Sants Pharmaceutical Co., Ltd. (CN) | 2026-02-11 | — | — | EP | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-5643943-A | NONSTEROIDAL ANTIINFLAMMATORY AGENTS FOR VASCULAR INFLAMMATION | ALCON LABORATORIES, INC. (US) | 1997-07-01 | — | — | US | claimed |
| EP-0767777-A1 | NEW SALTS OF 2- (2,6-DICHLOROPHENYL)AMINE]PHENYLACETOXYACETIC ACID WITH ORGANIC BASIC CATIONS | Novartis AG (CH) | 1997-04-16 | — | — | EP | claimed |
| EP-0759750-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO, Howard, K. (US) | 1997-03-05 | — | — | EP | claimed |
| US-5607966-A | BENZOFURAN OR BENZOPYRAN DERIVATIVES | ALCON LABORATORIES, INC. (US) | 1997-03-04 | — | — | US | claimed |
| WO-1996016639-A1 | NSAID DELIVERY EMPLOYING A POWDERED HYDROCOLLOID GUM OBTAINABLE FROM HIGHER PLANTS | CIBUS PHARMACEUTICAL, INC. (US) | 1996-06-06 | — | — | WO | claimed |
| WO-1996000716-A1 | NEW SALTS OF 2-[(2,6-DICHLOROPHENYL)AMINE]PHENYLACETOXYACETIC ACID WITH ORGANIC BASIC CATIONS | CIBA-GEIGY AG (CH) | 1996-01-11 | — | — | WO | claimed |
| WO-1995031194-A1 | COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES | SHAPIRO HOWARD K (US) | 1995-11-23 | — | — | WO | claimed |
| EP-0119932-B1 | NEW 2-((2,6-DICHLOROPHENYL)AMINE)PHENYLACETOXYACETYL DERIVATIVES, THE PROCESS FOR PREPARING THE SAME AND THEIR USE IN THERAPEUTICS | PRODES S.A. (ES) | 1987-05-13 | — | — | EP | claimed |
| US-4548952-A | ANTINFLAMMATORY, ANALGESIC AGENTS | PRODES, S.A. (ES) | 1985-10-22 | — | — | US | claimed |
| EP-0119932-A1 | New 2-((2,6-dichlorophenyl)amine)phenylacetoxyacetyl derivatives, the process for preparing the same and their use in therapeutics | PRODES S.A. (ES) | 1984-09-26 | — | — | EP | claimed |